Posted by Michael Wonder on 15 Apr 2020
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
14 April 2020 - Candidate vaccine expected to enter clinical trials in the second half of 2020 and, if successful, to be available in the second half of 2021.
Sanofi and GSK today announce that they have signed a letter of intent to enter into a collaboration to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic.
Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology. This technology has produced an exact genetic match to proteins found on the surface of the virus, and the DNA sequence encoding this antigen has been combined into the DNA of the baculovirus expression platform, the basis of Sanofi’s licensed recombinant influenza product in the US.
